Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Early Phase 1
2(50.0%)
Phase 3
1(25.0%)
Phase 1
1(25.0%)
4Total
Early Phase 1(2)
Phase 3(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06259578Early Phase 1Recruiting

UNAIR Inactivated COVID-19 Vaccine as Homologue Booster (Immunobridging Study)

Role: collaborator

NCT05918939Early Phase 1Unknown

UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study)

Role: collaborator

NCT05226429Phase 1Unknown

UNAIR Inactivated COVID-19 Vaccine

Role: collaborator

NCT05508477Phase 3Unknown

UNAIR Inactivated COVID-19 Vaccine Phase III (Immunobridging Study)

Role: collaborator

All 4 trials loaded